2023
Regimen Intensity and Age Affect Transplant-Related Outcomes after Matched Related Donor Hematopoietic Cell Transplantation for Sickle Cell Disease: A STAR Registry Study
John T, Chellapandian D, Shah R, Gillespie S, Liu K, Xiang Y, Bhatia M, Chaudhury S, Eckrich M, Guilcher G, Jaroscak J, Kasow K, Krajewski J, Ngwube A, Olson T, Rangarajan H, Horan J, Krishnamurti L, Shenoy S, Abraham A, Stenger E. Regimen Intensity and Age Affect Transplant-Related Outcomes after Matched Related Donor Hematopoietic Cell Transplantation for Sickle Cell Disease: A STAR Registry Study. Blood 2023, 142: 4904. DOI: 10.1182/blood-2023-182532.Peer-Reviewed Original ResearchHematopoietic cell transplantationRejection-free survivalAnti-thymocyte globulinSickle cell diseaseRelated donor hematopoietic cell transplantationDonor hematopoietic cell transplantationBu/CyShorter hospital stayCumulative doseSevere GVHDHospital stayOverall survivalCell transplantationCell diseaseDay 5Grade III/IVBu/cyclophosphamideBu/FluUse of alemtuzumabKaplan-Meier methodCurrent clinical trialsRisk of rejectionSmall cohort sizeSevere clinical phenotypeConditioning chemotherapyDonor Hemoglobin Genotype Does Not Impact Outcomes Following Matched Related Donor Hematopoietic Cell Transplantation for Sickle Cell Disease: A STAR Study
Stenger E, John T, Chellapandian D, Shah R, Gillespie S, Xiang Y, Liu K, Bhatia M, Guilcher G, Jaroscak J, Kasow K, Krajewski J, Ngwube A, Rangarajan H, Horan J, Krishnamurti L, Shenoy S, Abraham A. Donor Hemoglobin Genotype Does Not Impact Outcomes Following Matched Related Donor Hematopoietic Cell Transplantation for Sickle Cell Disease: A STAR Study. Blood 2023, 142: 4955. DOI: 10.1182/blood-2023-188514.Peer-Reviewed Original ResearchHematopoietic cell transplantationSickle cell diseaseDonor hematopoietic cell transplantationLong-term outcomesPost-HCTOrgan dysfunctionCell transplantationCell diseaseRelated donor hematopoietic cell transplantationSignificant differencesVaso-occlusive pain crisesComparable long-term outcomesLong-term outcome dataLast platelet transfusionMarkers of hemolysisCategorical variablesSymptom-free survivalSignificant organ dysfunctionHb AASickle cell traitContinuous variablesSevere clinical phenotypeSevere disease phenotypeChronic GVHDPain crisis
2021
Hematopoietic Cell Transplantation for Sickle Cell Disease
Krishnamurti L. Hematopoietic Cell Transplantation for Sickle Cell Disease. Frontiers In Pediatrics 2021, 8: 551170. PMID: 33469520, PMCID: PMC7813811, DOI: 10.3389/fped.2020.551170.Peer-Reviewed Original ResearchHematopoietic cell transplantationSickle cell diseaseAutologous hematopoietic progenitor cellsCell transplantationHematopoietic progenitor cellsDisease manifestationsCell diseaseRelated donor hematopoietic cell transplantationDonor hematopoietic cell transplantationEarly phase clinical trialsHaploidentical related donorsIntent of cureProgenitor cellsIschemic tissue damageLong-term ameliorationHaploidentical donorsEndothelial dysfunctionHLA-identicalLate complicationsRed blood cellsUnrelated HLAOrgan dysfunctionRelated donorsUnrelated donorsSCD patients